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A B S T R A C T
Acetaminophen (APAP) hepatotoxicity is characterized by an extensive oxidative stress. However, its source,
pathophysiological role and possible therapeutic potential if targeted, have been controversially described.
Earlier studies argued for cytochrome P450-generated reactive oxygen species (ROS) during APAP metabolism,
which resulted in massive lipid peroxidation and subsequent liver injury. However, subsequent studies
convincingly challenged this assumption and the current paradigm suggests that mitochondria are the main
source of ROS, which impair mitochondrial function and are responsible for cell signaling resulting in cell death.
Although immune cells can be a source of ROS in other models, no reliable evidence exists to support a role for
immune cell-derived ROS in APAP hepatotoxicity. Recent studies suggest that mitochondrial targeted
antioxidants can be viable therapeutic agents against hepatotoxicity induced by APAP overdose, and re-
purposing existing drugs to target oxidative stress and other concurrent signaling events can be a promising
strategy to increase its potential application in patients with APAP overdose.
1. Introduction
Acetaminophen (APAP) hepatotoxicity is the leading cause of acute
liver failure in many Western countries [1,2]. A key mechanism of the
toxicity is the cytochrome P450-catalyzed metabolic activation of
APAP, which generates the reactive metabolite N-acetyl-p-benzoqui-
none imine (NAPQI) and initiates toxicity in both rodents and humans
[3]. Excessive NAPQI formation after APAP overdose depletes cellular
glutathione (GSH), adducts proteins including mitochondrial proteins,
and induces mitochondrial oxidant stress and dysfunction. This results
in nuclear DNA fragmentation and necrotic cell death and a subsequent
inﬂammatory response, including the release of pro-inﬂammatory
cytokines and activation of immune cells [3]. Currently, APAP-induced
liver injury has served as the most popular, mechanistically well
studied and clinically relevant model for testing of phytotherapeutics
and other hepato-protective interventions. In spite of signiﬁcant
evidence pointing towards the existence of a general oxidative stress
during APAP hepatotoxicity, the cellular or intracellular sources and
the nature of the ROS in this context remain debatable. This has led to
controversial conclusions and ultimately jeopardized the translation of
new therapeutic approaches to the human pathophysiology [4,5]. In
particular, the pathophysiological role of ROS in the mechanism of
toxicity has not been clearly discussed and still requires further
investigation. This review will provide an updated overview of the
potential sources of ROS in APAP hepatotoxicity. The corresponding
pathophysiological role of each source in the toxicity will be also
summarized and discussed. We propose that mitochondrial targeted
antioxidants or re-purposing of existing drugs which target mitochon-
drial ROS may have therapeutic potential for APAP poisoning in
animals and potentially in humans.
2. Sources and relevance of oxidant stress in acetaminophen
hepatotoxicity
2.1. Cytochrome P450-mediated oxidant stress
In the 1980's, it was recognized that cytochrome P450-mediated
drug metabolism in microsomes can generate ROS (mainly superoxide
and hydrogen peroxide) [6]. Cytochrome P450 2E1-mediated ROS
production has been suggested to play a role in alcohol-induced liver
injury [7], although recent evidence suggests that mitochondria and
immune cell-derived oxidant stress can also contribute to the progres-
sion of the injury (Fig. 1) [8–10]. A mitochondrial oxidant stress has
also been implicated in the progression of I/R injury [11]. Since APAP
is also metabolized by P450 enzymes in microsomes, it was assumed
that P450-mediated metabolism of APAP generated ROS in APAP
hepatotoxicity, leading to subsequent lipid peroxidation and liver
injury [12]. This hypothesis was mainly based on the use of inducers
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and inhibitors of cytochrome P450, which enhanced and attenuated
APAP-induced lipid peroxidation, respectively [12]. However, this
conclusion was soon challenged by the fact that glutathione disulﬁde
(GSSG) formation, a sensitive indicator of hepatic oxidant stress, was
not increased during APAP metabolism in a rat model [13], and this
was subsequently conﬁrmed in a mouse study [14]. The original
observations in the rodent models were later supported in vitro. In
primary mouse hepatocytes, 2′,7′-dichloroﬂuorescein ﬂuorescence, a
marker of intracellular oxidant stress, did not change during drug
metabolism but rapidly increased after APAP was metabolized and
GSH was depleted [15]. Furthermore, in metabolically competent
human HepaRG cells, ROS and peroxynitrite were only detectable
after 6 h post-APAP, which is after APAP metabolism [16]. Another
interesting ﬁnding is that although in rats P450-mediated metabolism
of APAP also causes GSH depletion and even signiﬁcant protein
adducts formation, no increased oxidant stress or liver injury was
detected [17]. Taken together, these studies did not ﬁnd direct evidence
of APAP-induced oxidant stress during the metabolism phase.
However, recent ﬂuorescence measurements using highly sensitive
semiconducting polymer–based nanosensors provided evidence for
H2O2 formation during the metabolism phase of APAP in vivo [18].
The fact that this signal could be attenuated by P450 inhibitors
suggests that the oxidant stress was dependent on the drug metabolism
[18]. However, given the extensive evidence that many interventions
are highly eﬀective when given after the metabolism phase indicate that
these nanosensors are detecting a sub-toxic oxidant stress that may
have limited relevance for cell death.
2.2. Lipid peroxidation as mechanism of cell death
Lipid peroxidation (LPO) has been a frequently invoked mechanism
in ROS-induced cell death and liver injury [19–21]. Common initiators
of the peroxidation process are HO·and HOO·, which can be generated
through the Fenton Reaction. In addition, LPO can be caused by
peroxynitrite and heme dependent lipid peroxide decomposition [22].
The abstraction of H· from lipid molecules (mostly from polyunsatu-
rated fatty acids) produces fatty acid radicals. This initiates a free-
radical chain reaction that triggers the peroxidation of a large number
of target molecules, which would ultimately severely destroy the
integrity of cell membranes, damage the function of membrane bound
enzymes and even impair nuclear DNA. The involvement of LPO in the
pathophysiology of cell injury is typically assumed when parameters of
LPO (e.g., malondialdehyde, ethane and pentane exhalation, formation
of hydroxyfatty acids, hydroxynonenal, etc.) are increased in the
injured tissue, but decreased after an intervention that is thought to
act as an antioxidant. This is normally accompanied by improved liver
injury, leading to the conclusion that LPO is responsible for the cell
death [23–30]. Experimental evidence for the hypothesis that APAP
hepatotoxicity is caused by LPO was ﬁrst suggested by Wendel and
coworkers [31]. The recognition that the P450-mediated metabolism of
xenobiotics can release ROS in microsomes [6,32], and the fact that
inducers and inhibitors of P450 enzymes modulate APAP-induced LPO
and liver injury in mice in vivo supported the idea that P450 enzymes
were responsible for the oxidant stress [12]. Although there was no
doubt that there was severe LPO in the livers of these animals as
indicated by extensive ethane and pentane exhalation and high levels of
thiobarbituric acid-reactive substances (TBARs) [12,31,33]), the widely
overlooked fact was that the animals were fed a vitamin E-deﬁcient diet
high in polyunsaturated fatty acids, which made them exquisitely
sensitive to LPO induced by APAP or allyl alcohol [12,31,33,34].
Importantly, the massive LPO that occurred under these conditions (
> 50-fold increase of ethane exhalation and TBARS levels) caused
massive liver injury and acute liver failure within 4 h after APAP
overdose [12,33], and pretreatment with vitamin E or iron chelators
Fig. 1. Sources of ROS in APAP hepatotoxicity in comparison to other forms of liver injury. The cytochrome P450 enzyme system can generate free radicals during metabolism of
various compounds. Cyp2E1-mediated ROS formation during metabolism of alcohol has been show to play an important role in alcohol-induced liver injury, while the involvement of
mitochondria- and immune cell-derived ROS has also been implicated. With regards to acetaminophen (APAP)-induced liver injury, the reactive intermediate NAPQI generated during
APAP metabolism forms mitochondrial protein adducts, which cause oxidative stress within the organelle and subsequently initiate signaling cascades resulting in programmed necrosis.
In contrast to APAP injury, immune cells mediated oxidative stress is critical in liver injury-induced by conditions such as ischemia-reperfusion, where damage associated molecular
patterns (DAMPS) released from hepatocytes instigate free radical and chemokine production from Kupﬀer cells in the sinusoids, which then results in inﬁltration of neutrophils into the
space of Disse and further oxidant stress close to the hepatocyte, which ultimately produces mitochondrial oxidant stress and results in cell necrosis.
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dramatically reduced those LPO parameters and protected against the
injury [34–36]. Based on this evidence, it was concluded that APAP
triggers massive LPO, which is responsible for liver injury. However,
this only applies to animals with vitamin E-deﬁciency and cell
membranes high in polyunsaturated fatty acids. In contrast, when
animals were fed regular rodent chow, APAP caused severe liver injury
within 6–24 h, which was accompanied by no or very limited LPO [36].
Importantly, vitamin E treatment did not protect, suggesting that LPO
is not a relevant mechanism of cell death in APAP toxicity under
normal conditions [36].
Nevertheless, many recent studies on protection of natural products
with antioxidant eﬀects, still conclude that the LPO detected is
responsible for APAP-induced liver injury [23–30,37–39]. However,
since LPO is generally very limited in these studies, alternative
explanations for the protection can be oﬀ-target eﬀects of the natural
product, e.g. inhibition of drug metabolism [40]. Thus, under relevant
in vivo conditions, endogenous antioxidant defense systems including
vitamin E, glutathione peroxidase (GPx), thioredoxins and iron chela-
tion are generally suﬃcient to limit LPO after APAP overdose.
2.3. Mitochondrial oxidant stress
In recent years, mitochondria have been gradually recognized as the
main source of oxidant stress after an APAP overdose (Fig. 1) [3]. It is
well established that excessive NAPQI formation after APAP overdose
depletes GSH and binds to sulfhydryl groups of cellular proteins
[41,42]. Comparison of the subcellular protein adduct formation
between APAP versus its non-toxic regioisomer, 3′-hydroxyacetanilide
(AMAP) identiﬁed mitochondrial proteins as critical targets of NAPQI
in the initiation of toxicity, as indicated by the presence of mitochon-
drial adducts after APAP treatment but not after non-toxic AMAP
exposure in mice [43–45]. This concept is further supported by the
observation that AMAP toxicity in human hepatocytes is correlated
with mitochondrial adducts [46]. A number of mitochondrial proteins,
including GPx and ATP synthase α-subunit, have been shown to be
adducted by NAPQI (Fig. 2) [47]. Modiﬁcation of GPx reduced the
enzyme activity by 60% [48] while adduction of the ATP synthase α-
subunit might impair the ATP synthase function and cause the
cessation in ATP synthesis [48–50]. Though insuﬃcient to cause direct
cell death, cellular protein binding, especially mitochondrial protein
adduction, impairs mitochondrial respiration and causes oxidant stress
(Fig. 2) [49,51,52]. Although the direct molecular events that trigger
mitochondrial oxidant stress remain to be identiﬁed in APAP hepato-
toxicity, it is known that they interfere with the mitochondrial electron
transport chain (ETC), which causes leakage of electrons from the
chain and thus results in ROS formation (Fig. 2) [53]. Mitochondrial
complex I is a crucial site of ROS formation in mitochondria [54–56].
Interestingly, it was found that an overdose of APAP signiﬁcantly
increased complex I activity in mitochondria in APAP-treated mice,
and there was a strong positive correlation between complex I activity
and the severity of liver injury [57]. Metformin signiﬁcantly inhibited
complex I activity and resulted in a reduced oxidative stress and injury
[57]. In HepaRG cells, it was also observed that APAP induced proton
leakage from the ETC and impaired coupled respiration, and both were
inhibited by metformin treatment [57]. These observations support the
hypothesis that complex I is a critical source of ROS leakage in APAP
hepatotoxicity.
Electrons released from the ETC react with oxygen to form super-
oxide, which could either be dismutated to hydrogen peroxide and
molecular oxygen by manganese superoxide dismutase (MnSOD,
SOD2) in mitochondria or react with nitric oxide (NO) to form
peroxynitrite. The hydrogen peroxide produced by MnSOD can directly
react with GSH [58,59] or more likely be enzymatically detoxiﬁed by a
number of antioxidant enzymes in hepatocytes, such as catalase, GPx
or peroxiredoxins [60]. In contrast, peroxynitrite serves as a much
more potent oxidant and nitrating species in APAP hepatotoxicity
[58,61,62]. Consistent with this, a selective APAP-induced mitochon-
drial oxidant stress has been supported by multiple lines of evidence
including a speciﬁc increase of mitochondrial GSSG levels [49,50,62]
and the selective formation of nitrotyrosine protein adducts in mito-
Fig. 2. Mitochondrial oxidative stress and signaling in APAP hepatotoxicity. Metabolism of APAP forms the reactive metabolite NAPQI, which targets proteins, especially mitochondrial
proteins. Adduction of ATP synthase and glutathione peroxidase compromises generation of ATP through the electron transport chain and interferes with mitochondrial anti-oxidant
capacity. The enhanced generation of superoxide results in its reaction with nitric oxide to produce peroxynitrite, which ultimately produces oxidative/nitrosative stress. This then
activates the MAP kinase c-jun-N-terminal kinase (JNK), resulting in its phosphorylation and translocation to the mitochondria, which ampliﬁes the initial oxidative stress.
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chondria and the oxidative loss of mitochondrial DNA in APAP-treated
mice [63]. In addition, MitoSox Red staining, which speciﬁcally detects
mitochondrial superoxide, was observed in primary mouse hepatocytes
and in metabolically competent human HepaRG cells treated with
APAP [16,64]. Furthermore, isolated mitochondria from APAP-treated
mice were also shown to have elevated superoxide formation [57].
These observations together strongly support the existence of a
selective mitochondrial oxidant stress after APAP exposure.
The pathophysiological relevance of this mitochondrial oxidant
stress has also been extensively documented. It was shown that female
mice were less susceptible to APAP hepatotoxicity compared to males
due to the faster recovery of GSH in mitochondria, which detoxiﬁes
ROS and peroxynitrite resulting in less mitochondrial dysfunction [65].
Promoting the replenishment of hepatocellular GSH levels including
the mitochondrial content with exogenous GSH or its precursors was
shown to enhance the detoxiﬁcation of peroxynitrite and hydrogen
peroxide and eﬀectively protect against hepatotoxicity after APAP
overdose [50,58,66,67]. In contrast, mice with partial MnSOD-deﬁ-
ciency (MnSOD+/–) showed a much higher susceptibility to APAP
toxicity with increased peroxynitrite and protein carbonyl formation
[68,69]. Interestingly, MnSOD was shown to be nitrated and partially
inactivated by peroxynitrite after APAP [70], which might concurrently
increase the susceptibility of hepatocytes to ROS damage, especially
considering that the antioxidant GSH is severely depleted shortly after
APAP overdose [42]. Furthermore, the mitochondrial targeted antiox-
idant Mito-Tempo, which serves as a MnSOD mimetic [71], was highly
eﬀective in preventing APAP-induced oxidant stress and liver injury
[72]. Scavenging peroxynitrite with the natural product resveratrol also
eﬀectively protected against APAP hepatotoxicity [73]. Furthermore,
iron translocation from disrupted lysosomes into mitochondria pro-
motes the oxidant stress-induced mitochondrial permeability transi-
tion pore opening and necrotic cell death [74,75]. Taken together, this
suggests that targeting mitochondrial oxidant stress can be a promising
therapeutic target for treatment of APAP overdose in the clinic. Indeed,
one of the protective mechanisms of NAC, which is the only currently
available antidote for APAP overdose patients, is thought to be by
detoxifying ROS and reducing the oxidant stress in the liver [50]. Other
eﬀective antioxidants, especially mitochondrial targeted antioxidants
such as Mito-Tempo, would certainly be worth further investigation in
the clinical setting if its safety in humans can be veriﬁed.
2.4. Immune cell-derived oxidant stress
Another potential source of oxidant stress could be resident
macrophages (Kupﬀer cells) and inﬂammatory cells recruited into the
liver (monocytes/macrophages, neutrophils) (Fig. 1). Macrophages and
neutrophils mainly kill targets by reactive oxygen using NADPH
oxidase (NOX2) to generate superoxide and hydrogen peroxide, and,
in the case of neutrophils, use of myeloperoxidase to form the very
potent oxidant hypochlorous acid [76,77]. Direct cytotoxicity of
immune cell-derived ROS including hypochlorite has been implicated
in many liver pathologies, e.g., hepatic ischemia-reperfusion injury
[78,79], endotoxemia [80], and obstructive cholestasis [81]. Many of
these pathologies involve a sterile inﬂammatory component [82].
Similarly, the extensive necrotic cell death after APAP overdose also
triggers the release of damage-associated molecular patterns (DAMPs),
which includes high-mobility group box 1 protein (HMGB1) [83,84],
mitochondrial DNA and nuclear DNA fragments [85], heat shock
proteins [84], uric acid [86] and others. DAMPs mediate the activation
of resident macrophages (e.g., Kupﬀer cells) via toll-like receptors,
which lead to increased cytokine and chemokine formation and
immune cell accumulation in the liver (e.g., neutrophils and mono-
cyte-derived macrophages) [77,87]. Kupﬀer cells reside in sinusoids
and the generated ROS (e.g., NOX2-derived superoxide and hydrogen
peroxide) can cause cell injury in stressed hepatocytes [78]. However,
an involvement of Kupﬀer cells in the pathophysiology of APAP
hepatotoxicity has been highly controversial. Although it was originally
reported that mice pretreated with gadolinium chloride (GdCl3), an
intervention that inactivates Kupﬀer cells, had reduced peroxynitrite
formation and were protected against APAP-induced liver injury [88],
neither of these results could be reproduced by subsequent studies
[89–91]. In support of these later reports, mice functionally deﬁcient in
NADPH oxidase activity (gp91phox-/- mice) did not show a decreased
oxidative stress or reduced liver injury [92,93]. In addition, even
complete elimination of Kupﬀer cells by clodronate liposomes could
not protect against the injury [89]. Further evidence against the
importance of a Kupﬀer-derived oxidant stress during APAP toxicity
would be the fact that the most active Kupﬀer cells reside around the
periportal area [94], which cannot be responsible for cell death after
APAP where the necrotic cells are exclusively located in the centrilob-
ular areas of the liver. Taken together, these very diverse approaches
consistently argue against an involvement of a Kupﬀer cell-induced
oxidant stress in the pathophysiology.
Another potential source of oxidant stress after APAP overdose is
the inﬁltrating neutrophil. These phagocytes are the ﬁrst immune cells
to respond to the extensive APAP-induced necrosis [95]. However,
neutrophils do not only produce superoxide and hydrogen peroxide by
NADPH oxidase, but due to the presence of myeloperoxidase, these
cells can generate hypochlorite. Furthermore, in contrast to Kupﬀer
cells, neutrophils are mobile and can extravasate from sinusoids and
adhere to the targeted hepatocytes to be fully activated [96]. The
adherence to hepatocytes triggers a long-lasting oxidant stress in close
proximity to the target, which allows oxidants such as hydrogen
peroxide [97] and hypochlorous acid [79–81] to diﬀuse into hepato-
cytes and induce cell death (Fig. 1). The assumption for the involve-
ment of neutrophils in APAP hepatotoxicity came from studies showing
that the neutropenia-inducing antibody Gr-1 protected against APAP
hepatotoxicity [98,99]. However, it was recognized that the protection
was due to additional eﬀects of the antibody when the animal was
pretreated for 24 h [100]. Importantly, there was no direct evidence for
a neutrophil-derived oxidant stress in APAP hepatotoxicity [101].
Hypochlorite-modiﬁed proteins, which are markers of neutrophil-
derived oxidant stress, were not detectable after APAP in the liver
[101]. The hepatic or peripheral neutrophils were not activated or
primed for ROS formation at 6 h after APAP in mice [102] or 24–48 h
in humans [93], at which time liver injury is in full progress or has even
peaked. In addition, neither NADPH oxidase inhibitors nor deletion of
gp91phox, a subunit of NADPH oxidase, protected against APAP
hepatotoxicity [92,93,101]. Furthermore, neither increasing neutrophil
inﬁltration by administration of endotoxin or IL-1β nor preventing its
inﬁltration with antibodies against β2 integrins (CD18), or use of mice
deﬁcient in adhesion molecules such as intercellular adhesion mole-
cule-1 (ICAM-1) or CD18, aﬀected APAP hepatotoxicity [92,95,101–
103]. Together, these data suggest that neutrophils, despite their early
inﬁltration, are unlikely a relevant source of the oxidant stress after
APAP overdose.
Similar to neutrophils, monocytes are also recruited into the liver
after APAP hepatotoxicity [104]. Monocytes are recruited to the
necrotic area through an interaction of C-C chemokine receptor 2
(CCR2) on its membrane with monocyte chemoattractant protein-1
(MCP-1) generated by injured hepatocytes [105,106]. In contrast to the
relatively early recruitment of neutrophils, monocytes are typically
recruited into the liver within 12–24 h after an APAP overdose in mice,
which is past the peak of injury [106], suggesting that the inﬁltrating
monocytes (M2 macrophages) are not responsible for the injury but
might be important for the injury resolution. In support of this, M2
macrophages were shown to have a high capacity for phagocytosis and
can generate cytokines such as IL-10, which can stimulate tissue repair
[76,105,107]. In addition, mice deﬁcient in CCR2 or MCP-1 had
unaﬀected liver injury compared to wild type animals, but experienced
a reduced hepatic M2 macrophage recruitment and a substantial delay
in tissue repair [105–109]. These data suggest that M2 macrophages
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are involved in cell debris removal in the injury resolution phase after
APAP hepatotoxicity, which is a prerequisite for liver regeneration
[105,106,110]. Interestingly, this repair was not aﬀected in gp91phox-
deﬁcient mice, suggesting that ROS generated by macrophages or
neutrophils was not required for the cell debris removal process [93].
Of note, the ﬁndings in mice are consistent with clinical studies
suggesting a predominant repair and regenerative role for monocyte-
derived macrophages in APAP overdose patients [111]. Since it is well
known that there is a close link between oxidative stress and cell
proliferation [112–115], it will be particularly interesting to elucidate
the pathophysiological role of oxidative stress in the injury resolution
process after APAP hepatotoxicity in future investigations.
2.5. Xanthine oxidase and NAD(P)H quinone dehydrogenase 2 as
sources of ROS formation
Another potential source of ROS in the liver after APAP overdose
could be the enzyme xanthine oxidase. Indeed, it was observed that
xanthine dehydrogenase was converted to the oxidase in the liver after
APAP overdose, and mice pretreated with the xanthine oxidase
inhibitor allopurinol attenuated the oxidative stress and liver injury
[48,49], arguing for a potential involvement of xanthine oxidase in the
pathophysiology of APAP hepatotoxicity. However, careful analysis of
the data revealed that the dose of allopurinol required to protect
against APAP is 5–10-fold higher than the dose needed to completely
inhibit the enzyme, and a lower dose that completely inactivates the
enzyme could not reduce the oxidant stress or protect against the
toxicity [49]. Our follow-up studies demonstrated that the protection
by the high doses was actually caused by a preconditioning eﬀect
during aldehyde oxidase-mediated metabolism of allopurinol, which
induced metallothionein expression that can react with NAPQI and
ROS [116,117]. This is supported by evidence that neither 1 h
allopurinol pretreatment nor 18 h or 1 h oxypurinol (primary metabo-
lite of allopurinol) pretreatment protects against APAP-induced injury
[116]. These data argue against xanthine oxidase as a relevant source of
ROS in APAP hepatotoxicity.
Another source of superoxide during APAP toxicity was recently
proposed. The cytosolic protein NAD(P)H quinone dehydrogenase 2
(NQO2) can bind and metabolize APAP and generate superoxide
thereby causing a cellular oxidant stress [118]. Since NQO2 is highly
expressed in liver and kidney, it was hypothesized that this enzyme
might be a relevant source of the intracellular oxidant stress induced by
APAP [118]. Although these studies were performed in HeLa cells and
not in hepatocytes, there are additional issues to consider. The fact that
there is no biliary GSSG export during APAP toxicity argues against a
relevant oxidant stress in the cytosol [14,49]. In addition, as discussed
previously, the most relevant oxidant stress occurs after the metabo-
lism phase when mitochondrial protein adducts are formed [15,49] and
interventions that selectively aﬀect mitochondrial oxidant stress are
highly protective [68,69,72]. Thus, even if it can be veriﬁed that NQO2
can generate superoxide in hepatocytes, it is unlikely that NQO2 will be
a pathophysiologically relevant source of oxidant stress during APAP
hepatotoxicity.
3. The therapeutic potential of targeting mitochondrial
oxidant stress
N-acetylcysteine (NAC) was introduced as a clinical antidote
against APAP poisoning in 1970's [119]. Even today, it is still the only
pharmacological treatment option for APAP overdose patients. The
extensive mechanistic insights from the preclinical models have
proposed multiple protective mechanisms for NAC treatment (Fig. 3).
If it is given shortly after APAP overdose, i.e. within the metabolism
phase of APAP, NAC supplements the GSH pool as it is a synthetic
precursor and thus protects by detoxifying the reactive metabolite
NAPQI [120,121]. During the injury progression phase, the newly
synthesized GSH can also be transported into mitochondria, where it
can detoxify ROS and peroxynitrite [58,63]. Interestingly, it was also
reported that the surplus NAC in the circulation can be converted to
Krebs cycle intermediates, which support mitochondrial energy meta-
bolism and recovery of mitochondrial function [50]. These protective
mechanisms are supported by the varied eﬃcacy of NAC in overdose
patients. It is very obvious that the patients who beneﬁt most are those
receiving NAC within 8 h after APAP overdose, in which the replen-
ished GSH can detoxify NAPQI in the metabolism phase and prevent
the initiation of the injury [122,123]. Although the eﬀectiveness of NAC
declines at later times, the delayed administration is still beneﬁcial in
the clinic [122,123], probably by detoxifying ROS and supporting
mitochondrial energy metabolism. Unfortunately, in the clinic most
Fig. 3. Phases of hepatotoxicity after APAP overdose: Liver toxicity of APAP is initiated
after a metabolism phase, where the drug is metabolized by cytochrome P450 to generate
the reactive metabolite NAPQI. Excessive formation of NAPQI results in formation of
protein adducts, especially on mitochondrial proteins, which initiates the injury phase.
Mitochondrial protein adduct formation results in generation of reactive oxygen species
(ROS) within the organelle, which ultimately leads to activation of the mitochondrial
permeability transition and release of mitochondrial proteins such as apoptosis inducing
factor and endonuclease G and translocation to the nucleus. This then causes nuclear
DNA fragmentation and subsequently cell necrosis. Necrotic cells release damage
associated molecular patterns (DAMPs), which initiate the regeneration phase, with
inﬁltration of immune cells, and ultimately liver repair. Interventions which inhibit APAP
metabolism, as seen with a number of natural products, would consequently prevent
NAPQI generation and thus prevent hepatotoxicity. However, these types of therapeutics
would not be clinically beneﬁcial, since most patients present much later, i.e., at which
time the injury phase has already been initiated. N-acetylcysteine (NAC), which is the
current standard of care, protects by replenishing glutathione stores and scavenging
NAPQI, as well as supporting mitochondrial recovery. However, since it is eﬀective only
early during the injury phase, it may not be as beneﬁcial for patients who present late
after APAP consumption. Mitochondrial targeted antioxidants such as Mito Tempo, or
repurposed drugs such as Metformin, robustly prevent mitochondrial oxidative stress,
which attenuates downstream signaling and cell necrosis, and could be a future
therapeutic option. The eﬀect of ROS and antioxidants on the repair phase remains
unclear and deserves further investigation.
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APAP overdose patients only seek medical attention during or after the
peak of injury [124,125], at which time the eﬀectiveness of NAC has
already signiﬁcantly decreased [122,123]. Therefore, a pharmaceutical
intervention that still works during this late period would surely have
therapeutic potential and greatly help those late-presenting patients..
The protective eﬀect of NAC by detoxifying ROS encouraged the use
of antioxidants for late treatment of APAP poisoning. Indeed, numer-
ous interventions that can act as antioxidants have been shown to be
protective in preclinical models of APAP toxicity. For example, delayed
treatment with exogenous GSH or natural product resveratrol after
APAP metabolism signiﬁcantly decreased oxidative stress and pro-
tected against the injury [50,58,73]. In addition, pharmacological
inhibition of the JNK signaling pathway, which ampliﬁes the mito-
chondrial oxidant stress in APAP hepatotoxicity, reduced oxidant stress
and the subsequent injury [126,127]. However, despite massive
evidence in preclinical studies supporting a beneﬁcial potential of
antioxidants, no drugs that speciﬁcally target ROS are available
clinically for APAP overdose patients. There are several reasons for
this problem. First, due to the high eﬃcacy of the current standard-of-
care antidote NAC, any promising antioxidant has to be compared with
NAC, and only those that can provide additive protection to NAC
possess therapeutic potential. Interestingly in our recent studies, the
mitochondrial targeted antioxidant Mito-Tempo, either as a late
treatment alone or together with NAC oﬀered better protection than
NAC alone, which supports it as a therapeutic option for late treatment
of APAP overdose in patients (Fig. 3) [72]. Comparison of its eﬃcacy to
its analog Tempo highlights not only the importance of the mitochon-
drial oxidant stress in the development of APAP toxicity but also the
therapeutic potential of other mitochondrial targeted antioxidants [72].
It would be interesting to test the eﬃcacy of other antioxidants, e.g. the
mitochondria-targeting peptide Elamipretide [128], which is currently
in multiple clinical trials with FDA approval pending for primary
mitochondrial myopathy. Second, due to the high costs of de novo drug
development and the limited number of patients, it is unlikely that a
pharmaceutical company develops a drug speciﬁcally for APAP poison-
ing. Therefore, a better strategy for getting a new antidote against
APAP overdose would be by re-purposing an existing drug. For
example, an earlier study identiﬁed benzyl alcohol, a marketed drug
for treatment of head lice, as a promising intervention in APAP
hepatotoxicity [129], though a follow-up study revealed that the
protection of benzyl alcohol is mainly caused by inhibition of APAP
metabolism and thus is unlikely a realistic therapeutic option for
treatment of APAP overdose in patients [130]. Methylene blue, a
clinical used drug for diseases including methemoglobinemia and
psychiatric disorders, was shown to target to mitochondria and reduce
mitochondrial oxidant stress [131]. It also restored the compromised
ETC function and thus protected against APAP hepatotoxicity [131].
Recently, it was reported that metformin, a ﬁrst line drug for type 2
diabetes, attenuated the mitochondrial oxidant stress and protected
against APAP hepatotoxicity even as a late treatment (Fig. 3) [57]. In
addition, its eﬀectiveness can be reproduced in human HepaRG cells, a
clinically relevant model for APAP overdose [16], further supporting
metformin as a therapeutic option for patients [57]. Nevertheless, more
studies are still needed to establish its eﬀective therapeutic dose in
humans and assess potential side eﬀects of high doses of metformin
before its application in overdose patients.
4. Caveats of testing antioxidants in preclinical models
Research into natural products isolated from plants has revealed a
large number of potential drug candidates that may act as antioxidants.
The therapeutic potential of such interventions can only be assessed in
clinically relevant experimental models such as APAP hepatotoxicity
[4,132]. However, the frequent use of suboptimal preclinical models in
testing the eﬃcacy of antioxidants or other interventions has been a
signiﬁcant issue in recent years as experimental data from such studies
can lead to controversial mechanistic conclusions and thus hampering
the progress of translational research in testing antioxidants. For
example, the rat is widely regarded as a poor model since even high
overdoses of APAP do not cause relevant oxidant stress and liver injury
in these animals [17]. However, large numbers of studies testing
phytotherapeutics or other antioxidant interventions are still being
conducted in this model [4,40]. Furthermore, several human hepatoma
cell lines (e.g. HepG2, Hep3B, Huh7) are frequently used as in vitro
models in APAP studies. However, their human pathophysiological
relevance is questionable because of the lack of P450 enzymes for the
metabolic activation of APAP in these cells [133], which initiates the
toxicity in mice and humans. Even if an intervention, including an
antioxidant, shows protection in these cell lines, it may not be
therapeutically relevant for APAP overdose patients. In contrast, the
mouse model closely resembles the human pathophysiology and so far
has served as one of the most physiologically relevant models. The most
successfully applied in vitro model is primary mouse hepatocytes.
Although it has some limitations, such as the lack of non-parenchymal
cells and loss of P450 enzyme activity over time in culture, for an acute
model such as APAP-induced cell death, it generally reproduces most
aspects of the in vivo pathophysiology [132,134]. The HepaRG cell
model has been shown to closely resemble the human pathophysiology
for APAP overdose (except the requirement for JNK) [16,125]. Freshly
isolated primary human hepatocytes (PHH) are considered as gold
standard for drug toxicity studies and a recent investigation has
documented their relevance for the human pathophysiology in APAP
hepatotoxicity [135]. However, due to their limited availability and
high cost if commercially acquired, the use of PHH is still very limited
in APAP toxicity studies. Cryopreserved PHH have been introduced to
overcome these disadvantages, and currently more advanced PHH
culture systems like 3D culture or sandwich culture systems are being
developed to more closely represent the normal liver tissue architecture
[134]. Based on these caveats, any testing of new therapeutic inter-
ventions should be performed in human pathophysiologically relevant
models including primary mouse or human hepatocytes, HepaRG cells,
or the in vivo mouse model.
5. Summary and conclusions
Current experimental evidence demonstrates that neither drug
metabolism-induced oxidative stress nor extracellular ROS from
inﬂammatory cells are relevant sources of the oxidant stress in APAP
hepatotoxicity. In contrast, P450-mediated metabolism of APAP gen-
erates excessive amounts of the reactive metabolite NAPQI, which
targets mitochondrial proteins for adduct formation. This impairs
mitochondrial respiration and results in ROS formation, leading to
an overwhelming mitochondrial oxidant stress and mitochondrial
dysfunction. Despite the identiﬁcation of numerous potential thera-
peutic targets in mechanistic studies during the last decades, only very
few are likely to have clinical relevance. One of the therapeutic targets
that consistently comes up in many diﬀerent preclinical models
including human hepatocytes is the mitochondrial oxidant stress.
Thus, interventions that prevent or scavenge mitochondrial ROS and
peroxynitrite are currently the most promising therapeutic targets
against APAP hepatotoxicity in patients.
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